13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
40 檔
0.9%
As reported in its official Q1 2025 Form 13F filing, Alphabet Inc.'s tracked investment portfolio stood at $99.1B with 40 total positions.
During Q1 2025, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including FRSH, ARM, ASTS) accounted for 0.9% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | FRSH | Freshworks Inc-cl A | Stock-Other | 14.50% | -3.07% | — | |
| 2 | ARM | Arm Holdings Plc-adr | Stock-Tech | 13.28% | -6.69% | — | |
| 3 | ASTS | Ast Spacemobile Inc | Stock-Tech | 12.90% | -17.66% | — | |
| 4 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 9.27% | -7.41% | — | |
| 5 | ✓ | Stock-Other | 8.56% | — | — | ||
| 6 | GTLB | Gitlab Inc-cl A | Stock-Tech | 8.12% | -1.39% | -55.27% | |
| 7 | PL | Planet Labs Pbc | Stock-Industrials | 6.85% | -23.35% | — | |
| 8 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 4.74% | -1.66% | — | |
| 9 | PATH | Uipath Inc - Class A | Stock-Tech | 4.59% | -1.86% | — | |
| 10 | DXCM | Dexcom Inc | Stock-Healthcare | 4.49% | — | — | |
| 11 | ✓ | Verve Therapeutics Inc | Stock-Other | 3.58% | — | — | |
| 12 | PRME | Prime Medicine Inc | Stock-Other | 1.90% | -1.38% | — | |
| 13 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.68% | -0.99% | — | |
| 14 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 1.66% | — | -82.65% | |
| 15 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.43% | -0.27% | — | |
| 16 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.40% | -0.13% | — | |
| 17 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.40% | -0.18% | — | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 0.37% | -0.23% | — | |
| 19 | DM* | Desktop Metal Inc-a | Stock-Other | 0.34% | — | — | |
| 20 | SANA | Sana Biotechnology Inc | Stock-Other | 0.30% | -0.19% | — | |
| 21 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.26% | -0.36% | — | |
| 22 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 23 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.20% | — | — | |
| 24 | WGS | Genedx Holdings CORP | Stock-Other | 0.13% | — | — | |
| 25 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.12% | — | — | |
| 26 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 27 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.09% | — | — | |
| 28 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.08% | — | — | |
| 29 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.07% | -0.02% | — | |
| 30 | EXK | Exact Sciences CORP | Stock-Materials | 0.06% | — | — | |
| 31 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.06% | — | — | |
| 32 | GUTS | Fractyl Health Inc | Stock-Other | 0.05% | — | — | |
| 33 | HYPR | Hyperfine Inc | Stock-Other | 0.04% | -0.02% | — | |
| 34 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.04% | -0.05% | — | |
| 35 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.04% | — | — | |
| 36 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.03% | -0.02% | EXIT | |
| 37 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.02% | — | — | |
| 38 | ALEC | Alector Inc | Stock-Other | 0.01% | — | — | |
| 39 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — | |
| 40 | FULC | Fulcrum Therapeutics Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 40 disclosed positions in Q1 2025.
During Q1 2025, Alphabet Inc.'s top holdings by market value included FRSH (14.5%)、ARM (13.3%)、ASTS (12.9%). The largest single position, FRSH, represented 14.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2025, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.